Charles River Laboratories International (CRL) Current Deferred Revenue (2009 - 2026)

Charles River Laboratories International's Current Deferred Revenue history runs 17 years deep, the most recent figure standing at $210.4 million for Q4 2025.

• In Q4 2025, Current Deferred Revenue fell 15.26% year-over-year to $210.4 million; the TTM figure through Dec 2025 stood at $210.4 million (down 15.26% YoY), while the FY2025 annual figure was $210.4 million, down 15.26% from the prior year.
• Current Deferred Revenue for Q4 2025 stood at $210.4 million, down from $237.7 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $290.0 million in Q4 2022, with the low at $210.4 million in Q4 2025.
• The 5-year median for Current Deferred Revenue is $249.4 million (2024), against an average of $245.6 million.
• The sharpest annual moves came in 2021 and 2025: Current Deferred Revenue surged 35.75% in 2021, then decreased 15.26% in 2025.
• Charles River Laboratories International's Current Deferred Revenue stood at $219.7 million in 2021, then jumped by 32.0% to $290.0 million in 2022, then declined by 5.86% to $273.0 million in 2023, then declined by 9.04% to $248.3 million in 2024, then fell by 15.26% to $210.4 million in 2025.
• Business Quant data shows CRL's Current Deferred Revenue at $210.4 million in Q4 2025, $237.7 million in Q3 2025, and $268.3 million in Q2 2025.